Reversible anorgasmia with topiramate therapy for headache: A report of 7 patients

Christina Sun, Christine Lay, Susan Broner, Stephen Silberstein, Stewart Tepper, Lawrence Newman

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Objective. - To describe 7 patients who developed new onset anorgasmia while using topiramate therapy for migraine prophylaxis. Background. - Topiramate is an effective drug for the prevention of migraine headaches. Though it is generally well tolerated, it may be associated with a dose-related anorgasmia. Methods. - Case reports Results. - Seven patients (5 women, 2 men), between the ages of 40 and 62, developed anorgasmia while using topiramate for headache prevention. Four women and 2 men had migraine without aura, and 1 woman had migraine with aura. None had a prior history of anorgasmia or sexual dysfunction. Doses associated with this side effect ranged from 45 to 200 mg daily. All subjects had symptom resolution. Six patients had resolution within 7 days of discontinuing or decreasing the medication; the exact time frame of resolution for the seventh patient is unknown. Conclusion. - In our series, anorgasmia was a reversible, dose-related adverse effect of topiramate. Physicians need to be aware of the potential for topiramate to cause sexual side effects, and should inquire about these symptoms in patients for whom this agent has been prescribed.

Original languageEnglish
Pages (from-to)1450-1453
Number of pages4
Issue number9
StatePublished - Oct 2006
Externally publishedYes


  • Anorgasmia
  • Headache
  • Topiramate


Dive into the research topics of 'Reversible anorgasmia with topiramate therapy for headache: A report of 7 patients'. Together they form a unique fingerprint.

Cite this